CAR T Cell Therapy May Increase Risk Of Serious Heart Problems: Study

Patients who underwent a specialized stem cell therapy for cancer may face an increased risk of serious heart problems, according to the findings of a new study.

Researchers from the University of Pennsylvania report that more than 20% of patients who received anti-CD19 chimeric antigen receptor (CAR) T-cell therapy developed major cardiovascular side effects. The findings were published online last week in the medical journal JACC: CardioOncology.

The study focused on the cardiac side effects of CAR T-cell therapy used to treat patients with hematologic malignancies, including data on 145 adult patients undergoing the treatment. Of those, 36 patients had acute lymphocytic leukemia, 43 patients had diffuse large B-cell lymphoma, and 66 patients had chronic lymphocytic leukemia.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The researchers looked at the occurrence of major adverse cardiovascular events (MACE) among the patients. MACE events include cardiovascular death, symptomatic heart failure, acute coronary syndrome, ischemic stroke, and de novo cardiac arrhythmia.

Overall, 31 patients suffered a combined total of 41 MACE events. These events included 22 episodes of heart failure, 12 episodes of atrial fibrillation, two cases of acute coronary syndrome, two cardiac deaths, one episode of supra ventricular tachycardia, and one episode of non-sustained ventricular tachycardia.

The average time a patient suffered heart problems after having CAR T-cell infusion was 11 days.

A total of 61 patients died. All but two deaths were due to cardiac causes.

Cytokine release syndrome occurred 176 times in 104 patients. The average time to cytokine release syndrome occurrence after infusion was six days. Cytokine release syndrome is a recognized and potentially serious complication of CAR T-cell therapy.

Roughly 17% of patients had a MACE event within 30 days of T-cell infusion. Another 19% of patients had an event within 6 months and 21% at 12 months after infusion.

Patients who had major heart problems tended to be younger men with higher rates of cardiac risk factors at the time of treatment.

Adults who underwent the CAR T-cell therapy had refractory and relapsed lymphomas that were often treated with multiple rounds of anthracycline-based chemotherapy and chest radiation. Both treatments are established as having cardiotoxic effects and can lead to serious adverse heart events.

Other studies have shown cardiac complications in pediatric patients who were treated with CAR T-cell therapy. One study indicated more than one-third of patients developed cardiogenic shock.

“Patients treated with CAR T-cell therapy are at an increased risk for MACE and may benefit from cardiovascular surveillance,” the researchers concluded. “Given that CAR T cell use will only increase in the future and that no recommendations for monitoring and follow-up of left ventricular function and MACE currently exist, prospective studies are needed to ascertain the incidence and predictors of MACE.”


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.